Skip to main content

Advertisement

Table 1 Respondent demographics

From: Significant improvements in self-reported gastrointestinal tolerability, quality of life, patient satisfaction, and adherence with lopinavir/ritonavir tablet formulation compared with soft gel capsules

% Patients switching from SGCs BID to Tablets BID (%) Patients switching from SGCs BID or QD to Tablets QD (%)
Male/Female 85/15 76/24
Age:   
> 45 years 46 34
35–44 years 41 39
< 35 years 13 27
Duration of antiviral therapy   
≥ 5 years 59 41
1–5 years 31 49
< 1 year 10 10
Duration of LPV/r therapy   
SGC > 1 year 82 80
Tablet < 3 months 89 81